Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center

Journal of Microbiology, Immunology and Infection

Volumn 45, Issue 6, 2012, Pages 435-441

  Lin, Shang Yi ^a   Chen, Tun Chieh ^a,b   Chen, Feng Jui ^c   Chen, Yen Hsu ^a,b   Lin, Yee In ^a   Kristopher Siu, L ^b   Lu, Po Liang ^a,d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Glycopeptide; Hetero resistant vancomycin intermediate Staphylococcus aureus; Staphylococcal cassette chromosomes

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; LINEZOLID; MOXIFLOXACIN; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; BACTERIAL CHROMOSOME; BACTERIUM ISOLATE; CONTROLLED STUDY; EPSILOMETER TEST; GENE SEQUENCE; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; MORTALITY; MULTILOCUS SEQUENCE TYPING; NONHUMAN; OUTCOME ASSESSMENT; POPULATION; PREVALENCE; PULSED FIELD GEL ELECTROPHORESIS; SCREENING; STAPHYLOCOCCAL BACTEREMIA; TAIWAN; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL TYPING TECHNIQUES; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HOSPITAL MORTALITY; HOSPITALS, UNIVERSITY; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; STAPHYLOCOCCAL INFECTIONS; TAIWAN; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84870294035     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2012.05.004     Document Type: Article

References (35)

1. Fong R.K.C., Low J., Koh T.H., Kurup A. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur J Clin Microbiol Infect Dis 2009, 28:983-987.
2. Khosrovaneh A., Riederer K., Saeed S., Tabriz M.S., Shah A.R., Hanna M.M., et al. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2004, 38:1328-1330.
3. Charles P.G.P., Ward P.B., Johnson P.D.R., Howden B.P., Grayson M.L. Clinical features associated with bacteraemia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004, 38:448-451.
4. Maor Y., Rahav G., Belausov N., Ben-David D., Smollan G., Keller N. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteraemia in a tertiary care center. J Clin Microbiol 2007, 45:1511-1514.
5. Rybak M.J., Leonard S.N., Rossi K.L., Cheung C.M., Sadar H.S., Jones R.N. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008, 46:2950-2954.
6. Jones R.N. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006, 42:S13-S24.
7. Musta A.C., Riederer K., Shemes S., Chase P., Jose J., Johnson L.B., et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteraemia: Trends over 11 Years. J Clin Microbiol 2009, 47:1640-1644.
8. Gallon O., Lamy B., Laurent F., Reverdy M.E., Doucet-Populaire F., Decousser J.W. Antimicrobial susceptibility profiles of Staphylococcus aureus isolated in 2007 from French patients with bloodstream infections: goodbye hVISA, welcome Geraldine?. J Antimicrob Chemother 2010, 65:1297-1299.
9. Song J.H., Hiramatsu K., Suh J.Y., Ko K.S., Ito T., Kapi M., et al. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2004, 48:4926-4928.
10. Sun W., Chen H., Liu Y., Zhao C., Nichols W.W., Chen M., et al. Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. Antimicrob Agents Chemother 2009, 53:3642-3649.
11. Wang J.L., Tseng S.P., Hsueh P.R., Hiramatsu K. Vancomycin heteroresistance in methicillin-resistant Staphylococcus aureus. Taiwan. Emerg Infect Dis 2004, 10:1702-1704.
12. Ho C.M., Hsueh P.R., Liu C.Y., Lee S.Y., Chiueh T.S., Shyr J.M., et al. Prevalence and accessory gene regulator (agr) analysis of vancomycin-intermediate Staphylococcus aureus among methicillin-resistant isolates in Taiwan-SMART program, 2003. Eur J Clin Microbiol Infect Dis 2010, 29:383-389.
13. Fridkin S.K., Hageman J.C., Morrison M., Sanza L.T., Como-Sabetti K., Jernigan J.A., et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005, 352:1436-1444.
14. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
15. World Health Organization ATC index with DDDS 2003, WHO Collaborating Centre for Drug Statistics Methodology, Oslo.
16. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement 2007, Document M100-S17, CLSI, Wayne, PA.
17. Wootton M., MacGowan A.P., Walsh T.R., Howe R.A. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007, 45:329-332.
18. Wootton M., Howe R.A., Hillman R., Walsh T.R., Bennett P.M., MacGowan A.P. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001, 47:399-403.
19. Kondo Y., Ito T., Ma X.X., Watanabe S., Kreiswirth B.N., Etienne J., et al. Combination of multiplex PCRs for staphylococcal cassette chromosome mec type assignment: Rapid identification system for mec, ccr, and major differences in junkyard regions. Antimicrob Agents Chemother 2007, 51:264-274.
20. Enright M.C., Day N.P.J., Davies C.E., Peacock S.J., Spratt B.G. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 2000, 38:1008-1015.
21. Harmsen D., Claus H., Witte W., Rothgänger J., Claus H., Turnwald D., et al. Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J Clin Microbiol 2003, 41:5442-5448.
22. McDougal L.K., Steward C.D., Killgore G.E., Chaitram J.M., McAllister S.K., Tenover F.C. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003, 41:5113-5120.
23. Chen F.J., Lauderdale T.L., Huang I.W., Lo H.J., Lai J.F., Wang H.Y., et al. Methicillin-resistant Staphylococcus aureus in Taiwan. Emerg Infect Dis 2005, 11:1760-1763.
24. de Lassence A., Hidri N., Timsit J.F., Joly-Guillou M.L., Thiery G., Boyer A., et al. Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit. Clin Infect Dis 2006, 42:170-178.
25. Sng L.H., Koh T.H., Wang G.C.Y., Hsu L.Y., Kapi M., Hiramatsu K. Heterogeneous vancomycin-resistant Staphylococcus aureus (hetero-VISA) in Singapore. Int J Antimicrob Agents 2005, 25:177-179.
26. Van Hal S.J., Paterson D.L. The significance of heterogeneous vancomycin intermediate Staphylococcus aureus (hVISA) isolates: a systematic review and meta-analysis. Antimicrob Agents Chemother 2011, 55:405-410.
27. Sheng W.H., Wang J.T., Lauderdale T.L., Weng C.M., Chen D.L., Chang S.C. Epidemiology and susceptibilities of methicillin-resistant Staphylococcus aureus in Taiwan: emphasis on chlorhexidine susceptibility. Diagn Microbiol Infect Dis 2009, 63:309-313.
28. Ike Y., Arakawa Y., Ma X., Tatewaki K., Nagasawa M., Tomita H., et al. Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J Clin Microbiol 2001, 39:4445-4451.
29. Wong S.S.Y., Ho P.L., Woo P.C.Y., Yuen K.Y. Bacteraemia caused by Staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 1999, 29:760-767.
30. Assadullah S., Kakru D.K., Thoker M.A., Bhat F.A., Hussain N., Shah A. Emergence of low level vancomycin resistance in MRSA. Indian J Med Microbiol 2003, 21:196-198.
31. Kim H.B., Park W.B., Lee K.D., Choi Y.J., Park S.W., Oh M.D., et al. Nationwide surveillance for Staphylococcus aureus with reduced susceptibility to vancomycin in Korea. J Clin Microbiol 2003, 41:2279-2281.
32. Hsueh P.R., Chen W.H., Teng L.J., Luh K.T. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 2005, 26:43-49.
33. Lulitanond A., Engchanil C., Chaimanee P., Vorachit M., Ito T., Hiramatsu K. The first vancomycin-intermediate Staphylococcus aureus strains isolated from patients in Thailand. J Clin Microbiol 2009, 47:2311-2316.
34. Menezes G.A., Harish B.N., Sujatha S., Vinothini K., Parijal S.C. Emergence of vancomycin-intermediate Staphylococcus species in southern India. J Med Microbiol 2008, 57:911-912.
35. Wang J.T., Fang C.T., Chen Y.C., Wu C.L., Chen M.L., Chang S.C. Staphylococcal Cassette Chromosome mec in MRSA, Taiwan. Emerg Infect Dis 2007, 13:494-497.